Disrupting PD-1 signaling enhances the antiviral effector CD8+ T cell response to chronic infections in lymphoid tissues and improves the effector activity of tumor-infiltrating CD8+ T cells3,4. The gene discussed is CD8A; the disease is neoplasm.